Tranzyme bounces back from TPZ-102 trial failure with successful BMS research collaboration
This article was originally published in Scrip
Executive Summary
Tranzyme Pharma, a company developing mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders, has announced the successful completion of a chemistry-based drug discovery collaboration with New York-based biopharma, Bristol-Myers Squibb.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.